Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 3/20 | 0.88 |
| ▸ | TRPV1 | Q8NER1 | 8/20 | 0.35 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.34 |
| ▸ | PADI4 | Q9UM07 | 1/20 | 0.33 |
| ▸ | JAK2 | O60674 | 1/20 | 0.33 |
| ▸ | JAK1 | P23458 | 1/20 | 0.33 |
| ▸ | TYK2 | P29597 | 1/20 | 0.33 |
| ▸ | JAK3 | P52333 | 1/20 | 0.33 |
| ▸ | PIP4K2A | P48426 | 1/20 | 0.33 |
| ▸ | PIP4K2B | P78356 | 1/20 | 0.33 |
| ▸ | PIP4K2C | Q8TBX8 | 1/20 | 0.33 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2128074 | 0.94 | CYP3A4 (1.00) | CYP3A4TRPV1CRBNPADI4JAK2 | |
| SCHEMBL2128077 | 0.94 | CYP3A4 (1.00) | CYP3A4TRPV1CRBNPADI4JAK2 | |
| SCHEMBL1543113 | 0.90 | CYP3A4 (0.85) | CYP3A4TRPV1PADI4PDPK1 | |
| SCHEMBL2128091 | 0.90 | CYP3A4 (0.85) | CYP3A4TRPV1PADI4PDPK1 | |
| SCHEMBL2127937 | 0.89 | CYP3A4 (0.87) | CYP3A4TRPV1CRBNPADI4JAK2 | |
| SCHEMBL1542867 | 0.89 | CYP3A4 (0.87) | CYP3A4TRPV1CRBNPADI4JAK2 | |
| SCHEMBL1764858 | 0.88 | CYP3A4 (0.70) | CYP3A4TRPV1 | |
| SCHEMBL3189204 | 0.88 | CYP3A4 (0.85) | CYP3A4TRPV1CRBNPADI4JAK2 | |
| SCHEMBL3189211 | 0.88 | CYP3A4 (0.85) | CYP3A4TRPV1CRBNPADI4JAK2 | |
| SCHEMBL1764949 | 0.87 | CYP3A4 (0.68) | CYP3A4TRPV1CRBNPADI4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8383824-B2 | Heterocyclic antiviral compounds | ROCHE PALO ALTO LLC (US) | 2013-02-26 | — | — | US | claimed |
| US-8383824-B2 | Heterocyclic antiviral compounds | ROCHE PALO ALTO LLC (US) | 2013-02-26 | — | — | US | disclosed |
| EP-2501679-A1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | F. Hoffmann-La Roche AG (CH) | 2012-09-26 | — | — | EP | disclosed |
| WO-2011061243-A1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2011-05-26 | — | — | WO | disclosed |
| US-20110123489-A1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | ROCHE PALO ALTO LLC (US) | 2011-05-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110123489-A1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | HCCS, EIF2AK2, RNASE1 | CYP3A4 60/4885TRPV1 4149/4885CRBN 3075/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.